Compare MWC & VTVT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | MWC | VTVT |
|---|---|---|
| Founded | 2003 | 2015 |
| Country | Japan | United States |
| Employees | N/A | N/A |
| Industry | EDP Services | Biotechnology: Pharmaceutical Preparations |
| Sector | Technology | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 93.9M | 104.9M |
| IPO Year | 2025 | 2015 |
| Metric | MWC | VTVT |
|---|---|---|
| Price | $1.42 | $26.66 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 6 |
| Target Price | N/A | ★ $56.00 |
| AVG Volume (30 Days) | ★ 128.0K | 16.8K |
| Earning Date | 11-10-2026 | 11-09-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | N/A | N/A |
| Revenue Growth | ★ N/A | N/A |
| 52 Week Low | $0.78 | $20.04 |
| 52 Week High | $4.20 | $44.00 |
| Indicator | MWC | VTVT |
|---|---|---|
| Relative Strength Index (RSI) | 41.10 | 35.32 |
| Support Level | $1.34 | N/A |
| Resistance Level | $1.71 | $34.65 |
| Average True Range (ATR) | 0.16 | 1.39 |
| MACD | -0.02 | -0.15 |
| Stochastic Oscillator | 12.22 | 16.89 |
Micware Co Ltd is a Japan-based provider of software development services and inventive information technology (IT) solutions mainly focused on the automotive and mobility sectors. Its main focus is the development and sale of in-vehicle infotainment (IVI) systems that cover a broad range of modern car functionality from multimedia to navigation, human-machine interface, telematics, and driver assistance. The Group is also engaged in the development of navigation software and location information-based smartphone applications. Its reportable operating segments are: SDV (software-defined vehicles), LBS (location-based service), and Other. Maximum revenue is generated from the SDV segment. Geographically, the Group derives maximum revenue from Japan and the rest from international markets.
vTv Therapeutics Inc is a late-stage biopharmaceutical company focused on developing oral, small-molecule drug candidates intended to help treat people living with diabetes and other chronic diseases. Its clinical pipeline is led by cadisegliatin (TTP399), a novel, small-molecule, liver-selective glucokinase activator (GKA) currently being evaluated as a potential oral adjunctive therapy to insulin for the treatment of type 1 diabetes (T1D). In addition, the company is also engaged in the research and development of other candidates in its pipeline through collaborations with academic partners and license agreements, which include TTP273, HPP737, TTP-RA, Mavodelpar (HPP593), HPP971, and HPP3033, being studied and developed to counter various chronic diseases.